D-1862-2019 Class II Terminated
FDA drug recall D-1862-2019 was initiated by Torrent Pharma Inc. on Sep 6, 2019 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing. The recall status is terminated (terminated Nov 3, 2020). Affected quantity: 2472 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 25, 2019
- Initiation Date
- Sep 6, 2019
- Termination Date
- Nov 3, 2020
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2472 bottles
Product description
Anagrelide Capsules, USP, 0.5 mg, 100-count bottle, Rx only, Manufactured in India for: Torrent Pharma Inc., Basking Ridge, NJ 07920, NDC 13668-453-01.
Reason for recall
Failed Impurities/Degradation Specifications: High Out Of Specification results for impurities detected during routine stability testing.
Distribution pattern
Nationwide in the USA and Puerto Rico
Code information
Lot #: BFE2E003, Exp 08/31/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1862-2019
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026